Gimv : ImCheck to Present New Positive Data on ICT01 Monotherapy in Hematological Cancers at ESMO 2023 -October 19, 2023 at 02:27 am EDT

Interim data from Phase I dose escalation portion of EVICTION Phase I/IIa trial show strong safety profile and encouraging clinical activity for ICT01 monotherapy in relapsed/refractory...

Related Keywords

Madrid ,Spain ,Institut Paoli Calmettes ,Sylvain Garciaz ,European Society For Medical Oncology ,Department Of Hematology ,Imcheck Therapeutics ,European Society ,Medical Oncology ,Refractory Hematologic Cancers ,Acute Myeloid Leukemia ,Markets ,